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Abstract
Background: The effect of moderately elevated blood glucose levels among non-diabetic subjects on cancer
prognosis is not well described. The goal of this study was to examine the association of elevated random blood
glucose (RBG) levels in non-diabetic breast cancer patients with overall survival (OS) and time to tumor recurrence
(TTR).
Results: Forty-nine deaths and 32 recurrences occurred among 148 eligible study subjects during 855.44 person-years
of follow-up, with median follow-up of 5.97 years. We observed that patients with elevated RBG levels experienced
significantly shorter OS (hazard ratio [HR], 3.01; 95 % confidence interval [CI] (1.70–5.33); P < 0.001) and shorter
TTR (HR, 2.08; CI (1.04–4.16); P = 0.04) as compared to patients with non-elevated RBG levels. After controlling
for tumor grade, tumor stage, race, and BMI, elevated RBG continued to display high and statistically significant
association with shorter OS (HR, 3.50; CI (1.87–6.54); P < 0.001). Adjustment for age, race, and BMI strengthened HR of
RBG for TTR. The association of RGB with TTR lost its borderline statistical significance upon controlling for both tumor
grade and stage.
Conclusions: The data suggest that elevated blood glucose is associated with poor prognosis of breast cancer
patients. Given the potential clinical implication, these findings warrant further investigation.
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Background
Numerous epidemiologic studies indicate that type 2 dia-
betes is associated with an increased risk of breast cancer
[1–6]. Several large studies that compared cancer-related
mortality between subjects with and without diabetes sug-
gested an association between increased mortality and dia-
betes for breast cancer [1, 7–9]. However, the contribution
of other factors including the delay in diagnosis, lower use
of effective adjuvant therapies, diabetes-prescribed drug
use, and diabetes-related comorbidities on observed associ-
ation between diabetes and breast cancer is not clearly
addressed [9–20]. To manage the unpredictable impact of
the confounding factors on the observational studies, Boyle
et al. [21] investigated the association of elevated blood
glucose and breast cancer risk in women without diabetes
and reported a small increase in breast cancer risk in a
meta-analysis study. With regard to the published data,
studying breast cancer outcome among non-diabetic sub-
jects with elevated blood glucose levels is clearly needed.
Random blood glucose (RBG) values ≥120 mg/dL have
been shown to have 90–92 % specificity for detection of
any glucose intolerance that include patients with pre-
diabetes and undiagnosed diabetes [22, 23]. We adopted
RBG values of 120 mg/dL or higher to be an indication of
disorders in glucose metabolism [22, 24], and performed a
retrospective cohort study to evaluate the relationship
between elevated blood glucose levels and survival of non-
diabetic breast cancer subjects. We observed that elevated
RBG levels correlate with poor prognosis in breast cancer
patients independently of age, tumor characteristics, race,
and BMI.
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Methods
Study design and characteristics of patient population
This was a retrospective chart-review cohort study that
was performed according to a protocol approved by the
UAMS Institutional Review Board (IRB). The UAMS
IRB determined the study to met the criteria for exempt
status per 45 CFR 46, meaning there was no requirement
to obtain informed consent from the study subjects. A
cohort was formed by including subjects diagnosed with
breast cancer from 1995 to 2000. African-American (AA)
and European-American (EA) women who were ≥18 years
of age at diagnosis, and who had at least one RBG meas-
urement from 1 year before cancer diagnosis to the time
of diagnosis, were included. Patients with a diagnosis of
diabetes at any time before cancer diagnosis to the last
follow-up date were excluded. Patients with documented
disease stages I, II, and III were included, whereas patients
with stage IV (metastatic) disease were excluded. A total
of 148 patients were identified, all of whom were treated
at the hospital of University Arkansas for Medical Sciences
(UAMS). The dates of diagnosis, tumor recurrence, and
last follow-up, vital status, and disease status at the last
follow-up, age, race, tumor stage and grade were provided
by the UAMS tumor registry. RBG, height, and weight
were extracted from the medical-record charts.
Outcome and predictor variables
There were two measures of outcome: overall survival
(time to death by any reason with censoring occurring at
last contact when patient was still alive) and time to
tumor recurrence (with censoring at death or last con-
tact). Measured RBG levels were classified as “high” or
“elevated” if ≥120 mg/dL versus “low” or “non-elevated”
if <120 mg/dL, and this dichotomous classification was
used as the main predictor variable. The RBG measure-
ments evaluated in this study included data collected
within a 1-year period prior to the diagnosis, and were
averaged together if multiple numbers were recorded to
reach a single measurement for each patient. Height,
weight, age, and race were recorded at the time of diag-
nosis. BMI (trichotomized as ≥30, <30, and unknown),
race (AA vs. EA), age (as a continuous variable), tumor
grade (as a categorical variable), and stage (as a categor-
ical variable) were used as covariates.
Statistical analysis
Survival and time to tumor recurrence in the high and low
RBG groups were visualized using Kaplan-Meier curves
and compared for differences with the log-rank test. After
confirming the validity of the proportional-hazards as-
sumption, outcomes were analyzed for covariate associa-
tions using univariate and multivariate Cox-regression
analyses. In order to avoid overfitting the multivariate Cox
models, we required every model to have a minimum of 10
observed events per covariate [25]. This meant that the
maximum number of predictor variables in a multivariate
Cox model was five for analysis of overall survival (OS)
and three for analysis of time to tumor recurrence (TTR).
Hazard ratios (HRs) with 95 % confidence intervals were
calculated for each covariate. All hypothesis tests were
two-sided; all P values were reported numerically, and eval-
uated using an alpha = 0.05 significance level. IBM SPSS
Statistics Version 22 (IBM Corp., Armonk, NY) software
was used for statistical analyses.
Results
Characteristics of patient population
Forty-nine deaths and 32 recurrences occurred among
148 eligible study subjects during 855.44 person-years of
follow-up, with median follow-up of 5.97 years. Distribu-
tions of selected variables in studied population are sum-
marized in Table 1. Of the total number of the patients,
120 (81 %) were EA and 28 (19 %) were AA women.
Most patients (123, 83 %) were diagnosed with stage II
breast cancer, although 20 (14 %) and 5 (3 %) of total eli-
gible subjects were respectively diagnosed with stages I
and III disease. Sixty-eight patients (46 %) were diagnosed
with pathological grade III tumors versus 54 (36 %) with
grade II and 26 (18 %) with grade I. Age was distributed
with a minimum, median, and maximum age of 28, 53,
and 89 years, respectively.
Elevated RBG correlates with poor prognosis and shorter
time to tumor recurrence
We adopted RBG values of 120 mg/dL or higher to be
an indication of disorders in carbohydrate metabolism
[22, 24]. An RBG cutoff value of 120 mg/dL has been
shown to have 90–92 % specificity in the detection of
any glucose intolerance, which includes patients with
pre-diabetes and undiagnosed diabetes [22, 23]. We per-
formed survival analysis to evaluate the association of
high RBG, a likely representative of pre-diabetes, with
patients’ survival and time to tumor recurrence. Patients
with elevated RBG had significantly shorter overall
survival and time to tumor recurrence (Fig. 1). Subjects
in elevated RBG group had a median ± SE of 6.05 ± 0.65
for OS. Median OS was not reached for subjects with
low RBG. Neither of the study subpopulations reached
median TTR.
Association of RBG with survival persists after controlling
for tumor characteristics, age, BMI, and race
Tumor grade and tumor stage are the common prognos-
tic factors that correlate with recurrence and survival
endpoints. Race also affects survival, since AA breast
cancer patients experience shorter survival time than
their EA counterparts [26]. RBG levels may associate
with BMI. Therefore, the association of RBG with both
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OS and TTR was evaluated after controlling for age,
tumor grade, tumor stage, BMI, and race (Table 2). RBG
level of ≥120 mg/dL was associated with a shorter OS
(hazard ratio [HR] = 3.01; 95 % confidence interval [CI],
(1.70–5.33); P < 0.001), and a shorter time to tumor recur-
rence (HR, 2.08; CI (1.04–4.16), P = 0.039). In univariate
analysis, none of the other variables showed significant
association with OS, and only age displayed a significant
association with TTR (HR, 0.96; CI (0.94–0.99), P = 0.01).
Controlling for tumor grade, tumor stage, or age did not
appreciably change the HR value of RBG for OS (Table 2).
However, adjustment for these three covariates combined
led to a 6 % increase in the HR value of RBG for OS, from
3.01 to 3.19 (Table 2). The addition of race to this model
(adjusting for age, tumor grade, tumor stage, and race)
barely affected the associations of RBG with OS. Control-
ling for BMI improved association of RBG with OS (HR
increased from 3.01 to 3.24, an 8 % increase). After adjust-
ing for tumor grade, tumor stage, race, and BMI, the HR
value of RBG for OS increased by 16 % (HR, 3.50; CI
(1.87–6.54); P < 0.001). With respect to TTR, controlling
for age led to a 25 % increase in the HR value of RBG
compared to its value from univariate analysis (Table 2).
Adjusting for both tumor grade and tumor stage slightly
weakened RBG’s association with TTR, as the HR dropped
from 2.08 before adjustment to 2.00 (a 4 % decrease) after
adjustment, but the weakening was enough to render the
HR statistically insignificant. Adjusting for BMI strength-
ened the association of RBG and TTR where HR in-
creased to 2.37 from 2.08 (a 14 % increase). The HR of
TTR with RBG showed consistent increases over the
crude estimate after controlling for either BMI and grade
or BMI and stage (Table 2). These data suggest that RBG
levels in breast cancer patients correlate with patients’
survival and probably recurrence of the disease.
Discussion
Our study revealed that breast cancer patients with elevated
RBG levels have shorter OS and TTR. Epidemiological
a
b
Fig. 1 Kaplan-Meier analysis of RBG and patients’ survival. High RBG
levels are associated with shorter overall survival (a) and shorter time
to tumor recurrence (b). RGB values of ≥120 mg/dL were considered
high. P values were estimated using log-rank test. Green, RBG ≥ 120;
blue, RBG < 120. Plus signs indicate censoring
Table 1 Characterization of the studied population
Characteristics RBG < 120 RBG≥ 120 Total P value
No. (%) No. (%) No. (%)
All patients 95 (64 %) 53 (36 %) 148 (100 %)
Age 0.02
Min 29 28 28
Max 89 85 89
Mean (SD) 53.3 (13.3) 57.4 (12.9) 54.80 (13.3)
Median 50 56 53.0
<50 45 (47 %) 15 (28 %) 60 (41 %)
≥50 50 (53 %) 38 (72 %) 88 (59 %)
Tumor grade 0.14
Grade I 21 (22 %) 5 (9 %) 26 (18 %)
Grade II 34 (36 %) 20 (38 %) 54 (36 %)
Grade III 40 (42 %) 28 (53 %) 68 (46 %)
Tumor stage 0.19
Stage I 16 (17 %) 4 (8 %) 20 (14 %)
Stage II 75 (79 %) 48 (91 %) 123 (83 %)
Stage III 4 (4 %) 1 (2 %) 5 (3 %)
Race 0.05
EA 82 (86 %) 38 (72 %) 120 (81 %)
AA 13 (14 %) 15 (28 %) 28 (19 %)
BMI 0.1
Min 17 21 17
Max 54 43 54
Mean (SD) 28.5 (6.8) 30.3 (6.3) 29.1 (6.6)
Median 27 29 27
<30 61 (64 %) 25 (47 %) 49 (33 %)
≥30 28 (29 %) 21 (40 %) 86 (58 %)
Unknown 6 (6 %) 7 (13 %) 13 (9 %)
Death 20 (41 %) 29 (59 %) 49 (100 %)
Recurrence 16 (50 %) 16 (50 %) 32 (100 %)
Median follow-up (years) 6.27 5.14 5.97
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studies strongly suggest an association between high blood
glucose and mortality in breast cancer patients [9]. In a
study examining the general population, Saydah et al. [27]
classified the subjects as having either diagnosed diabetes,
undiagnosed diabetes, impaired glucose tolerance, or nor-
mal glucose tolerance, and went on to observe that individ-
uals with impaired glucose tolerance had the highest
adjusted relative hazard of cancer mortality compared to
the reference group with normal glucose tolerance. Con-
sistently, our data suggest that RBG, which is a non-fasting
blood glucose measurement, has a significant association
with breast cancer outcomes, particularly with OS.
Controlling for tumor grade, tumor stage, and age sug-
gests that RBG can be considered as an independently
significant factor that correlates with overall survival.
Age displayed a strong confounding effect on the RBG
association with TTR, such that controlling for age ac-
centuated the RBG association by 25 %. On the other
hand, the prognostic significance of RBG for TTR, which
was already at borderline, crossed the border into insig-
nificance upon controlling for tumor grade and stage.
Strengthening of the HR of RBG for OS after adjusting
for race or BMI suggests that these two covariates con-
found the association of RBG with patients’ survival. A
similar phenomenon was observed regarding the associ-
ation of RBG with TTR. Therefore, race and BMI should
be considered as major confounders in the design and
conduct of future studies.
A diabetic population is a heterogeneous group to be
studied for cancer mortality for at least three reasons.
First, clinical diagnosis of diabetes often leads to treatment
with anti-diabetic medications that reduce blood glucose,
thus reducing the impact of diabetes on the tumor, and
potentially introducing a source of variability when a
given anti-diabetes drug may directly affect the tumor
[12, 18–20, 28]. Second, there may be disease-dependent
variation in glucose and insulin levels in diabetics. Third,
there is a complex set of relationships between diabetes
and cancer, and an incomplete understanding of under-
lying biological mechanisms associating these two health
issues. Similar factors as above may contribute to hetero-
geneity of the grouping and play well into low power of
the analyses. The fact that we observed a strong associ-
ation between RBG and survival may suggest that RBG
screening may have significant clinical implications. Pre-
diabetes is a condition that occurs when a person’s blood
glucose levels are higher than normal, though not high
enough for a diagnosis of diabetes. People with pre-
diabetes develop insulin resistance and are at an increased
risk of type 2 diabetes. Measuring RBG levels has been
proposed as an easy-to-measure and reliable predictor of
pre-diabetes and early diabetes [22, 24]. Screening for high
RBG may pick patients with undiagnosed early diabetes or
in the pre-diabetes stage. Therefore, lack of drug use and
being early in the process of development of the disease
makes such a group of patients a relatively homogenous
one, allowing to reduce confounders and improve confi-
dence levels compared to cancer studies on diabetics or
obese populations.
High glucose levels may be accompanied with high insu-
lin levels. Insulin enhances cell growth and promotes cell
proliferation due to its mitogenic effects [29]. High levels of
insulin were associated with distant recurrence and poor
survival [30–32]. We were not able to separate the impact
of blood glucose and insulin on the survival endpoints. The
possibility that breast cancer further increased the levels of
RBG cannot be excluded, which is a limitation of this study.
Moreover, treatment for breast cancer may increase RBG
further, and adversely affect survival [33]. For example, the
glucocorticoid Dexamethasone, which is widely used to
prevent side effects during chemotherapy, is associated with
elevation of blood glucose [34]. The use of this drug may
unevenly affect patients with elevated RGB than those with
low RGB levels. We were not able to address this issue, and
further studies are required to explore these possibilities.
Table 2 Hazard ratios for the association between RBG (≥120
vs. <120) and breast cancer outcomes
Overall survival HR (95 % CI) P value
Crude 3.01 (1.70–5.33) <0.001
Adjusted for age 2.99 (1.68–5.33) <0.001
Adjusted for age group (≥50 vs. <50) 3.07 (1.72–5.48) <0.001
Adjusted for grade 3.08 (1.71–5.57) <0.001
Adjusted for stage 3.09 (1.73–5.53) <0.001
Adjusted for age, tumor grade and
tumor stage
3.19 (1.74–5.86) <0.001
Adjusted for age, tumor grade, tumor
stage, and race
3.24 (1.75–5.99) <0.001
Adjusted for age group (≥50 vs. <50),
tumor grade, tumor stage, and race
3.40 (1.83–6.33) <0.001
Adjusted for BMI 3.24 (1.78–5.89) <0.001
Adjusted for tumor grade, tumor stage,
race, and BMI
3.50 (1.87–6.54) <0.001
Time to tumor recurrencea
Crude 2.08 (1.04–4.16) 0.039
Adjusted for age 2.59 (1.27–5.26) 0.009
Adjusted for age group (≥50 vs. <50) 2.65 (1.29–5.44) 0.008
Adjusted for grade 2.06 (1.01–4.18) 0.046
Adjusted for stage 2.01 (1.00–4.04) 0.051
Adjusted for grade and stage 2.00 (0.97–4.09) 0.059
Adjusted for race 2.17 (1.08–4.38) 0.030
Adjusted for BMI 2.37 (1.16–4.83) 0.017
Adjusted for BMI and grade 2.32 (1.13–4.73) 0.021
Adjusted for BMI and stage 2.32 (1.13–4.76) 0.022
aFive out of 148 (3.4 %) subjects who never became disease free were
removed from TTR analyses
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The hormone-receptor details needed to identify basal-
like disease were not available for this study, and, therefore,
we were not able to rule in or out any contribution for the
breast cancer subtypes in the observed association between
survival and RBG. Therefore, we cannot exclude the possi-
bility that differences in the prevalence of triple-negative
cancers contributed to the poorer survival among patients
with high blood glucose. Other limitations of this study
are small sample size and lack of cancer-specific mor-
tality data that potentially can affect the outcome of
this study. Availability of pre-diagnosis blood sugar
measurement, while could have increased homogeneity
may have also introduced unknown factors in selection
of the patient population. Therefore, these results should
be interpreted with caution.
Conclusions
This study suggests that hyperglycemia, a component of
pre-diabetes and undiagnosed early diabetes, affects sur-
vival of breast cancer patients. Therefore, a routine meas-
urement of blood glucose may potentially give guidance on
mortality risk for breast cancer patients. As the prevalence
of disorders in carbohydrate metabolism grows, the popu-
lation of breast cancer patients with this disorder is also
growing, and our study suggests that these patients tend to
experience shorter survival than patients with normal
blood glucose levels. Our findings could represent a great
public health issue and therefore warrant further investiga-
tion in larger cohorts.
Abbreviations
AA: African American; BMI: body mass index; CI: confidence interval;
EA: European American; HR: hazard ratio; IRB: Institutional Review Board;
OS: overall survival; RBG: random blood glucose; TTR: time to tumor
recurrence; UAMS: University of Arkansas for Medical Sciences.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BMK initiated the study and was in charge of the protocol and initial accruing
of the data. He led the data collection, management, and analysis. He finalized
statistical analysis and drafted the manuscript. RG, VK, and SM worked on initial
cohort data, identified the subjects, extracted the data from various databases
and medical records, and validated the data. FJ worked on data preparation
and participated in some initial analyses of the data. ERS participated in
the statistical analysis and guiding through statistical approaches, he also
participated in drafting and writing the manuscript. BJF reviewed and improved
the manuscript and guided through some advanced analyses. AMS, LFH, and
TKE participated in design and conduction of the study and in interpretation of
the results and helped draft the manuscript. All authors included deserve the
authorship right and they read and approved the final manuscript.
Acknowledgements
The project described was supported by the Translational Research Institute,
grant UL1TR000039 through the NIH National Center for Research Resources
and National Center for Advancing Translational Sciences to BMK. The content
is solely the responsibility of the authors and does not necessarily represent the
official views of the NIH. The funding agency did not have any role in
the design, collection of the data, analysis or interpretation of the data.
Author details
1Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical
Sciences, Little Rock, AR 72205, USA. 2Department of Pathology, University of
Arkansas for Medical Sciences, 4301 West Markham St., Slot #824, Little Rock,
AR 72205, USA. 3Division of Hematology/Oncology, University of Arkansas for
Medical Sciences, Little Rock, AR 72205, USA. 4Department of Biostatistics,
University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
5Department of Epidemiology, University of Arkansas for Medical Sciences,
Little Rock, AR 72205, USA.
Received: 28 July 2015 Accepted: 16 March 2016
References
1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a
predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol.
2004;159(12):1160–7.
2. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes
mellitus and breast cancer: a retrospective population-based cohort study.
Breast Cancer Res Treat. 2006;98(3):349–56.
3. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Increased
prevalence of prior breast cancer in women with newly diagnosed diabetes.
Breast Cancer Res Treat. 2006;98(3):303–9.
4. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between diabetes
mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J
Cancer Prev. 2011;12(4):1061–5.
5. Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD.
The association of diabetes with breast cancer incidence and mortality in
the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012;
23(7):1193–203. doi:10.1007/s10552-012-9989-7.
6. Chen HF, Liu MD, Chen P, Chen LH, Chang YH, Wen PC, et al. Risks of breast
and endometrial cancer in women with diabetes: a population-based cohort
study. PLoS One. 2013;8(6), e67420. doi:10.1371/journal.pone.0067420.
7. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific
malignancies in type 2 diabetic patients from Verona. Diabetes Care.
2003;26(4):1047–51.
8. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al.
Clinically defined type 2 diabetes mellitus and prognosis in early-stage
breast cancer. J Clin Oncol. 2011;29(1):54–60. doi:10.1200/JCO.2010.29.3183.
9. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, et al. Diabetes
mellitus and breast cancer outcomes: a systematic review and meta-
analysis. J Clin Oncol. 2011;29(1):40–6. doi:10.1200/JCO.2009.27.3011.
10. Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS.
Screening mammogram utilization in women with diabetes. Diabetes Care.
2001;24(12):2049–53.
11. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related
mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Diabetes Care. 2006;29(2):254–8.
12. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim
L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer
in patients with diabetes. J Clin Oncol. 2007;25(12):1476–81. doi:10.1200/
JCO.2006.07.2777.
13. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of
diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008;
109(2):389–95.
14. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Insulin-sensitizing
therapy attenuates type 2 diabetes-mediated mammary tumor progression.
Diabetes. 2010;59(3):686–93. doi:10.2337/db09-1291.
15. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and
cancer mortality rates in type 2 diabetes: assessing effects of time-varying
exposure. Diabetologia. 2010;53(8):1631–7. doi:10.1007/s00125-010-1750-8.
16. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU,
et al. Type 2 diabetes mellitus and medications for type 2 diabetes
mellitus are associated with risk for and mortality from cancer in a
German primary care cohort. Metabolism. 2011;60(10):1363–71. doi:10.
1016/j.metabol.2010.09.012.
17. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer
mortality reduction and metformin: a retrospective cohort study in type 2
diabetic patients. Diabetes Obes Metab. 2012;14(1):23–9. doi:10.1111/j.1463-
1326.2011.01480.x.
Monzavi-Karbassi et al. Cancer & Metabolism  (2016) 4:7 Page 5 of 6
18. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, et al.
The impact of treatment noncompliance on mortality in people with type 2
diabetes. Diabetes Care. 2012;35(6):1279–84. doi:10.2337/dc11-1277.
19. Ranc K, Jorgensen ME, Friis S, Carstensen B. Mortality after cancer among
patients with diabetes mellitus: effect of diabetes duration and treatment.
Diabetologia. 2014;57(5):927–34. doi:10.1007/s00125-014-3186-z.
20. Wu JW, Boudreau DM, Park Y, Simonds NI, Freedman AN. Commonly used
diabetes and cardiovascular medications and cancer recurrence and cancer-
specific mortality: a review of the literature. Expert Opin Drug Saf. 2014;
13(8):1071–99. doi:10.1517/14740338.2014.926887.
21. Boyle P, Koechlin A, Pizot C, Boniol M, Robertson C, Mullie P, et al. Blood
glucose concentrations and breast cancer risk in women without diabetes: a
meta-analysis. Eur J Nutr. 2013;52(5):1533–40. doi:10.1007/s00394-012-0460-z.
22. Ziemer DC, Kolm P, Foster JK, Weintraub WS, Vaccarino V, Rhee MK, et al.
Random plasma glucose in serendipitous screening for glucose intolerance:
screening for impaired glucose tolerance study 2. J Gen Intern Med. 2008;
23(5):528–35.
23. Rolka DB, Narayan KM, Thompson TJ, Goldman D, Lindenmayer J, Alich K,
et al. Performance of recommended screening tests for undiagnosed
diabetes and dysglycemia. Diabetes Care. 2001;24(11):1899–903.
24. Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Caudle JM, et al.
Age, BMI, and race are less important than random plasma glucose in
identifying risk of glucose intolerance: the Screening for Impaired Glucose
Tolerance Study (SIGT 5). Diabetes Care. 2008;31(5):884–6.
25. Somorjai RL, Dolenko B, Baumgartner R. Class prediction and discovery
using gene microarray and proteomics mass spectroscopy data: curses,
caveats, cautions. Bioinformatics. 2003;19(12):1484–91.
26. Hunt BR, Whitman S, Hurlbert MS. Increasing Black:White disparities in
breast cancer mortality in the 50 largest cities in the United States. Cancer
Epidemiol. 2014;38(2):118–23. doi:10.1016/j.canep.2013.09.009.
27. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance
and the risk of cancer death in the United States. Am J Epidemiol. 2003;
157(12):1092–100.
28. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes
mellitus on complications and outcomes of adjuvant chemotherapy in
older patients with breast cancer. J Clin Oncol. 2009;27(13):2170–6. doi:10.
1200/JCO.2008.17.5935. Epub 2009 Mar 23.
29. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B.
Effect of insulin on cell cycle progression in MCF-7 breast cancer cells.
Direct and potentiating influence. J Biol Chem. 2001;276(41):38023–8.
30. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al.
Fasting insulin and outcome in early-stage breast cancer: results of a
prospective cohort study. J Clin Oncol. 2002;20(1):42–51.
31. Borugian MJ, Sheps SB, Kim-Sing C, Van Patten C, Potter JD, Dunn B, et al.
Insulin, macronutrient intake, and physical activity: are potential indicators
of insulin resistance associated with mortality from breast cancer? Cancer
Epidemiol Biomarkers Prev. 2004;13(7):1163–72.
32. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al.
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal
women. J Natl Cancer Inst. 2009;101(1):48–60. doi:10.1093/jnci/djn415.
33. Ji GY, Jin LB, Wang RJ, Bai Y, Yao ZX, Lu LJ, et al. Incidences of diabetes and
prediabetes among female adult breast cancer patients after systemic
treatment. Med Oncol. 2013;30(3):687. doi:10.1007/s12032-013-0687-4.
34. Hickish T, Astras G, Thomas P, Penfold S, Purandare L, Hickish TF, et al. Glucose
intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer
Inst. 2009;101(7):537.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Monzavi-Karbassi et al. Cancer & Metabolism  (2016) 4:7 Page 6 of 6
